We found that LINC01963 silencing enhanced the chemosensitivity of PC3-DR cells to DTX, indicating that LINC01963 is a potential therapeutic target for treating patients with prostate cancer with DTX resistance. Here, LINC01963 is linked to prostate carcinoma.